Understand the source comparison
Do Peptides Help with Infection? — Comparison of Mechanisms and Applications
Before selecting a peptide approach for infection management, understanding how different peptide classes compare in mechanism, timeframe, and pathogen specificity is essential. Antimicrobial Peptides (LL-37, Defensins) Direct membrane disruption via electrost
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide approach for infection management, understanding how different peptide classes compare in mechanism, timeframe, and pathogen specificity is essential.
- Antimicrobial Peptides (LL-37, Defensins)
- Direct membrane disruption via electrostatic binding and pore formation
- 15–60 minutes for bacterial killing at therapeutic concentration
- Gram-positive bacteria (MIC 2–16 μg/mL), Gram-negative bacteria (MIC 8–64 μg/mL), enveloped viruses
- Limited oral bioavailability, proteolytic degradation in GI tract, high production cost ($200–800/mg)
- Best for topical or local application where direct delivery to infection site is feasible. Systemic use remains experimental
- Thymic Peptides (Thymalin, Thymosin α-1)
- T-cell maturation and differentiation, restoration of cellular immunity
- 5–14 days for measurable immune parameter changes
- Prophylaxis against opportunistic infections in immunocompromised states, post-surgical infection prevention
- No direct antimicrobial activity, requires functional thymus, effect size modest (40–60% infection rate reduction)
- Prophylactic tool for at-risk populations. Not acute infection treatment
- Cationic Host Defense Peptides (Polymyxin B, Colistin)
- Outer membrane disruption in Gram-negative bacteria via LPS binding
- 2–6 hours for bactericidal effect at therapeutic dose
- Multidrug-resistant Gram-negative bacteria (Pseudomonas, Acinetobacter, Klebsiella)
- Dose-limiting nephrotoxicity (15–25% incidence), neurotoxicity at high doses, resistance emerging
- Reserved for last-resort treatment of carbapenem-resistant infections. Benefit-risk calculation required
- Immunomodulatory Peptides (KPV, BPC-157)
- Downregulation of pro-inflammatory cytokines, enhancement of tissue repair
- 3–7 days for anti-inflammatory effects, 2–4 weeks for infection prevention
- Inflammatory conditions predisposing to secondary infection (IBD, chronic wounds)
- Indirect infection benefit, limited human clinical trial data, dosing not standardised
- Adjunctive approach for chronic inflammatory states. Not standalone antimicrobial therapy